Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKY01
- Development stage
- Preclinical
- Lead developer
- SEEKYO Therapeutics
- Modality
- Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Physical Methods → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
SKY01 is a preclinical chemotherapy drug candidate developed by Seekyo for the treatment of solid tumors. It utilizes therapeutic vectors that are specifically activated by enzymes within the tumor microenvironment, offering a potential alternative to Antibody-Drug Conjugates (ADCs). The drug is currently undergoing toxicology and pharmacokinetics studies to prepare for future clinical trials.
02
Targets
GUSB (Beta-glucuronidase)
Beyond the preview
Go deeper on SKY01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKY01.